Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sugar-Free Actiq "Approvable" Pending Chemistry, Manufacturing Clearance

This article was originally published in The Pink Sheet Daily

Executive Summary

Cephalon describes outstanding issues as "technical" in nature and expects final approval within six months. The sugar-free formulation was developed in response to post-marketing reports of dental cavities, the company says.

You may also be interested in...



Cephalon Likely To Launch In-House Actiq Generic To Compete With Barr

Cephalon is planning to launch an in-house generic version of Actiq (transmucosal fentanyl) to compete with Barr, the company said

Cephalon/Cima Merger Contingent On Granting Generic Actiq License To Barr

Barr's generic version of Actiq would enter the market when FDA approves Cima's fentanyl product, but no later than February 2007. The companies expect the merger to close in the next few days.

NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter

DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter

Topics

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel